Assembly Biosciences, Inc. (ASMB)
| Previous close | 13.41 |
| Open | 13.66 |
| Bid | 13.20 x 100 |
| Ask | 13.49 x 100 |
| Day's range | 13.14 - 13.66 |
| 52-week range | 7.68 - 20.04 |
| Volume | |
| Avg. volume | 27,614 |
| Market cap | 72.482M |
| Beta (5Y monthly) | 0.61 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Assembly Biosciences Reports Fourth Quarter and Year End 2023 Financial Results and Recent Highlights
Four candidates planned to be in clinical development in 2024 with interim data from two studies anticipated by year end Clinical development timelines accelerated for ABI-5366; now anticipating interim data from Phase 1a available in 3Q2024, initiation of Phase 1b in individuals with recurrent genital herpes by end of 2024 and interim Phase 1b data available in 1H2025Gilead Sciences, Inc. partnership supports advancement and strengthening of antiviral pipeline targeting serious viral diseases S
- GlobeNewswire
Assembly Biosciences Announces Effective Date of Reverse Stock Split
– Assembly Bio common stock expected to begin trading on a split-adjusted basis on February 12, 2024 – SOUTH SAN FRANCISCO, Calif., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today announced that it expects a 1-for-12 reverse stock split of its outstanding shares of common stock will be effective as of February 9, 2024. The company anticipates that its common s
- GlobeNewswire
Assembly Biosciences Provides Anticipated Development Milestones for 2024
Four development candidates anticipated to be in the clinic by the end of 2024, reflecting expansion of R&D portfolio across herpesviruses and hepatitis B and D virusesInitial clinical data anticipated by end of year from first-in-human study of long-acting helicase-primase inhibitor targeting recurrent genital herpes (ABI-5366) and Phase 1b study of next-generation core inhibitor for chronic hepatitis B virus (ABI-4334)Recently announced long-term partnership with Gilead Sciences, Inc. (Gilead)
